Several drugs have been shown to reduce migraine symptoms, or elicits migraine-like attacks [3]. Studies, both in man and in experimental animals, have revealed anti-migraine effects of triptans, gepants (calcitonin gene-related peptide (CGRP) antagonists) and CGRP antibodies [4–7]. However, due to the size and the pharmacokinetics of these drugs it is suggested that only a modest passage may occur across the blood-brain barrier (BBB) [8]. The published figures on BBB passage are in the vicinity of 3 % when given at clinically effective doses of triptans/gepants [5, 9–11]. While these molecules have a small size, the CGRP antibodies will not likely cross the BBB at all and therefore unlikely to antagonize receptor sites within the CNS [5].